Kv7 K +通道代表了用于治疗包括癫痫在内的各种神经系统疾病的有吸引力的药理靶标。在本文中,已合成了42个原型Kv7激活剂瑞替加滨构象受限的类似物,并通过电生理膜片钳实验作为Kv7激动剂进行了测试。与瑞替加滨(0.93±0.43μM)相比,化合物23a增强Kv7.2电流的EC50(0.08±0.04μM)较低,而24a(0.63±0.07μM)的效力未见变化。此外,与瑞替加滨相比,23a和24a在激活异聚Kv7.2 / Kv7.3和同聚Kv7.4通道方面也显示出更高的效力。分子模型研究为结合位点的最佳相互作用所需的化学特征提供了新的见解。稳定性研究表明,与瑞替加滨相比,化学稳定性提高了23a和24a。总体而言,本发明结果突出了N5-烷基酰胺基吲哚部分为设计化学稳定的,高效的和选择性的Kv7激动剂提供了合适的药效学支架。
A novel amine derivative expressed by general formula (1)
(in the formula: G
1
, G
2
, and G
3
are the same or different and represent CH or a nitrogen atom; R
1
represents a chlorine atom, an optionally-substituted C
3-8
cycloalkyl group, or the like; R
2
represents —COOR
5
(in the formula, R
5
represents a hydrogen atom or a carboxyl protective group), or the like; R
3
represents a hydrogen atom, or the like; and R
4
represents an optionally-substituted condensed bicyclic hydrocarbon group, an optionally-substituted bicyclic heterocyclic group, or the like), or a salt thereof is useful in procedures such as the treatment or prevention of conditions related to excessive keratinocyte proliferation.